Antitrust Antitrust

Bristol Myers Squibb’s $10.8 million settlement in HIV drug antitrust case will get final approval, US judge says

By Michael Acton
  • 17 Nov 2022 22:43
  • 17 Nov 2022 22:43
Bristol Myers Squibb will get final approval of its antitrust settlement with a class of direct purchasers of HIV drugs, the California federal judge overseeing the litigation said today.

The litigation against Gilead, Bristol Myers Squibb, Janssen Pharmaceuticals, Johnson & Johnson, and Teva Pharmaceuticals alleges a conspiracy to block generic drugs used to

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News